Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
0.8016
USD
|
-2.52%
|
|
-1.99%
|
-60.71%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
321.2
|
170.6
|
874.3
|
287.6
|
194.5
|
87.03
|
-
|
-
|
Enterprise Value (EV)
1 |
193.4
|
-0.4267
|
672.7
|
272.4
|
236.3
|
101.2
|
37.18
|
-147.3
|
P/E ratio
|
-3.19
x
|
-1.41
x
|
-13.5
x
|
-2.61
x
|
-1.7
x
|
-0.79
x
|
-0.89
x
|
-0.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
73.6
x
|
42.3
x
|
18.1
x
|
14.4
x
|
11.9
x
|
5.29
x
|
1.94
x
|
7.26
x
|
EV / Revenue
|
44.3
x
|
-0.11
x
|
14
x
|
13.7
x
|
14.5
x
|
6.15
x
|
0.83
x
|
-12.3
x
|
EV / EBITDA
|
-2.08
x
|
0
x
|
-9.77
x
|
-2.39
x
|
-1.79
x
|
-0.63
x
|
-0.21
x
|
0.82
x
|
EV / FCF
|
-1.91
x
|
0
x
|
-5.45
x
|
-2.24
x
|
-1.87
x
|
-0.58
x
|
-0.2
x
|
0.58
x
|
FCF Yield
|
-52.3%
|
21,705%
|
-18.3%
|
-44.7%
|
-53.4%
|
-171%
|
-506%
|
173%
|
Price to Book
|
2.43
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
35,806
|
43,307
|
67,988
|
83,366
|
95,342
|
108,569
|
-
|
-
|
Reference price
2 |
8.970
|
3.940
|
12.86
|
3.450
|
2.040
|
0.8016
|
0.8016
|
0.8016
|
Announcement Date
|
3/11/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.365
|
4.037
|
48.21
|
19.94
|
16.34
|
16.47
|
44.87
|
11.99
|
EBITDA
1 |
-93.2
|
-99.37
|
-68.86
|
-113.9
|
-132
|
-160.8
|
-173.8
|
-179.1
|
EBIT
1 |
-97.94
|
-106
|
-75.21
|
-120.4
|
-139.6
|
-137.8
|
-147.4
|
-200.7
|
Operating Margin
|
-2,243.76%
|
-2,626.13%
|
-155.99%
|
-603.8%
|
-854.26%
|
-836.98%
|
-328.47%
|
-1,674.29%
|
Earnings before Tax (EBT)
1 |
-94.43
|
-105.3
|
-75.08
|
-119.7
|
-138.5
|
-128.8
|
-130.7
|
-183.2
|
Net income
1 |
-94.43
|
-105.3
|
-75.08
|
-119.7
|
-138.5
|
-133
|
-138.7
|
-183.2
|
Net margin
|
-2,163.41%
|
-2,609.31%
|
-155.73%
|
-600.09%
|
-847.34%
|
-807.78%
|
-309.07%
|
-1,528.03%
|
EPS
2 |
-2.810
|
-2.790
|
-0.9500
|
-1.320
|
-1.200
|
-1.017
|
-0.9000
|
-1.140
|
Free Cash Flow
1 |
-101.2
|
-92.62
|
-123.4
|
-121.8
|
-126.2
|
-173.5
|
-188.2
|
-254.3
|
FCF margin
|
-2,318.08%
|
-2,294.2%
|
-255.99%
|
-610.77%
|
-772.27%
|
-1,053.7%
|
-419.58%
|
-2,121.42%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.064
|
7.191
|
5.471
|
3.021
|
4.262
|
2.443
|
1.955
|
1.565
|
10.38
|
1.742
|
1.933
|
10.95
|
14.68
|
75.5
|
60.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.78
|
-28.96
|
-29.67
|
-29.88
|
-31.92
|
-34.82
|
-35.73
|
-38.6
|
-30.47
|
-39.8
|
-39.3
|
-33.55
|
-32.3
|
-29
|
-29.5
|
Operating Margin
|
-972.06%
|
-402.77%
|
-542.28%
|
-988.98%
|
-748.92%
|
-1,425.13%
|
-1,827.52%
|
-2,466.71%
|
-293.47%
|
-2,284.79%
|
-2,032.72%
|
-306.52%
|
-219.99%
|
-38.41%
|
-48.76%
|
Earnings before Tax (EBT)
1 |
-29.77
|
-28.92
|
-29.52
|
-29.97
|
-31.29
|
-33.98
|
-35.26
|
-38.43
|
-30.82
|
-40.38
|
-39.68
|
-30.78
|
-29.04
|
-30.3
|
-31
|
Net income
1 |
-29.77
|
-28.92
|
-29.52
|
-29.97
|
-31.29
|
-33.98
|
-35.26
|
-38.43
|
-30.82
|
-40.38
|
-39.68
|
-30.78
|
-29.04
|
-30.3
|
-31
|
Net margin
|
-971.57%
|
-402.11%
|
-539.48%
|
-991.92%
|
-734.16%
|
-1,390.99%
|
-1,803.38%
|
-2,455.85%
|
-296.81%
|
-2,318.31%
|
-2,052.23%
|
-281.16%
|
-197.78%
|
-40.13%
|
-51.24%
|
EPS
2 |
-0.3600
|
-0.3400
|
-0.3400
|
-0.3500
|
-0.3000
|
-0.3000
|
-0.3100
|
-0.3300
|
-0.2600
|
-0.3400
|
-0.3017
|
-0.2183
|
-0.2033
|
-0.2200
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/9/23
|
5/11/23
|
8/9/23
|
11/8/23
|
3/5/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
41.8
|
14.2
|
-
|
-
|
Net Cash position
1 |
128
|
171
|
202
|
15.2
|
-
|
-
|
49.8
|
234
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.3165
x
|
-0.0882
x
|
-
|
-
|
Free Cash Flow
1 |
-101
|
-92.6
|
-123
|
-122
|
-126
|
-174
|
-188
|
-254
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
3.700
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.530
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
16.2
|
-
|
-
|
-
|
4.57
|
5.5
|
6.6
|
7.9
|
Capex / Sales
|
370.52%
|
-
|
-
|
-
|
27.97%
|
33.4%
|
14.71%
|
65.9%
|
Announcement Date
|
3/11/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
0.8016
USD Average target price
4.333
USD Spread / Average Target +440.59% Consensus |
1st Jan change
|
Capi.
|
---|
| -60.71% | 87.03M | | -1.64% | 90.28B | | -0.66% | 39.5B | | -15.83% | 31.71B | | +61.79% | 26.41B | | -21.68% | 14.34B | | -8.73% | 12.89B | | -10.32% | 11.8B | | -45.77% | 10.95B | | +3.15% | 8.85B |
Biopharmaceuticals
|